Komodo Health AI vs OpenAI API

Enterprise licensing to pharmaceutical companies, health systems, and payers. No public pricing. Contact for pricing.

Free $5 in trial credits for new accounts. Usage-based per token: GPT-4o at $2.50/million input tokens, $10/million output tokens. o1 at $15/million input tokens. Realtime API at $5/million audio tokens. Enterprise volume discounts.

Patient health data de-identified under HIPAA de-identification standards. Access requires data use agreements and IRB approval for research purposes. Review Komodo's data governance framework.

Default API users: review OpenAI's data handling policy. Enterprise API: data not used for model training, with data handling agreements. Zero Data Retention option available for sensitive use cases.

• ✓330 million patient longitudinal data coverage is one of the most comprehensive US real-world health datasets
• ✓Integrated claims, lab, and EHR data provides richer patient journey evidence than single-source datasets
• ✓Pulse SaaS interface makes real-world evidence accessible without custom database development
• ✓Pharmaceutical market access teams can generate regulatory-grade evidence from real-world data

• ✓Most widely used AI API with the broadest developer ecosystem
• ✓Well-documented with official SDKs for major programming languages
• ✓Realtime API enables low-latency voice AI applications
• ✓Function calling and structured output enable reliable application patterns

• ✕Enterprise-only licensing appropriate for pharmaceutical companies and large health systems with analytics budgets
• ✕Real-world data has limitations — claims-based patient identification is less accurate than clinical data
• ✕Regulatory acceptance of real-world evidence varies by market and indication — not a substitute for clinical trials

• ✕More expensive than competing APIs for some models
• ✕o1 reasoning model pricing is high for cost-sensitive workloads
• ✕Vendor lock-in risk without multi-provider architecture